EMERYVILLE, Calif., Dec. 11 /PRNewswire-FirstCall/ -- Bionovo Inc. announced today that Dr. Terry Speed will join the company's scientific advisory board.
Terry Speed, Ph.D., is a professor in the Department Statistics at the University of California, Berkeley and Senior Principal Research Scientist and head of the Bioinformatics Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia. At the university and the institute, Dr. Speed teaches graduate-level statistics and bioinformatics and is co- investigator on genetic, genomic and systems biology projects.
"Making sense of the massive amounts of data now available to us is critical to the understanding of health and disease. My collaboration with Dr. Leitman at UCSF and Bionovo is an exciting new adventure in analyzing biological data," said Dr. Speed.
Dr. Speed has served on a number of academic scientific advisory boards such as the Mathematical Biosciences Institute at Ohio State University, the Department of Energy's Joint Genome Institute, CA, the Department of Biology of the Ecole Normale Superieure, Paris, France, and the Department of Statistics, Oxford University, UK. He is a member of the International Statistical Institute since 1987 and is a fellow of the Australian Academy of Sciences. He was awarded the 2002 Pitman Medal (Statistical Society of Australia), the 2003 Moyal Medal (Macquarie University), and was the joint recipient of 2004 Outstanding Applications Paper Award, American Statistical Association. Dr. Speed has served as a consultant to various industry companies such as Stillwater Sciences, Berkeley, CA, GeneData, AG, Basel, Switzerland, Gene Logic, Inc, Gaithersberg, MD, and Affymetrix, Inc, Santa Clara, CA. Dr. Speed is recognized as one of the world's leaders in the emerging field of Bioinformatics. He brings to Bionovo more than 35 years of experience in biostatistics, more recently specializing in the design and analysis of studies in genetics and genomics.
"We are honored to add Dr. Speed to our team of physicians and scientists on our current scientific advisory board," said Isaac Cohen, Bionovo's president and chief executive officer. "Bionovo is employing genomic, proteomic and metabolomic techniques in order to better understand systems biology of its targets and the toxicology of our drugs. Terry's knowledge will significantly improve our ability to apply the most sophisticated analytical methods to our data."
Bionovo, Inc.
Bionovo is a drug development company focusing on the discovery of novel pharmaceutical agents for cancer and women's health. The company has two drugs in clinical testing: MF101 in Phase 2 for quality of life conditions associated with menopause and BZL101 in Phase 1/2 for the treatment of advanced breast cancer. The company has an additional pipeline of drugs in development for breast cancer, pancreatic cancer and other menopausal symptoms with a total of 5 candidates expected to be in clinical trials by the end of 2007. The company is developing its products in close collaboration with leading U.S. academic research centers, including the University of California, San Francisco, University of Colorado Health Sciences Center, University of California, Berkeley, and the University of Texas Southwestern Medical Center in Dallas, TX. For further information please visit: http://www.bionovo.com.
Forward-Looking Statements
This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.
Bionovo, Inc.CONTACT: Jim Stapleton, Chief Financial Officer of Bionovo, Inc.,+1-510-601-2000 or jim@bionovo.com; Media: Jennifer Larson, +1-415-409-2729or jlarson@labfive.com, for Bionovo, Inc.; or Investors: Antima "Taz"Sadhukhan of Investor Relations Group, +1-212-825-3210, for Bionovo, Inc.
Web site: http://www.bionovo.com/
